1 Under-$10 Stock Set to Surge as Much as 963% in 2026 [Yahoo! Finance]
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
In most sectors, that kind of upside is almost unheard of. Some biotech stocks, however, are an exception. When encouraging clinical data and regulatory milestones align, a single breakthrough can rapidly reprice a biotech stock. That is precisely why Wall Street expects this under-$10 biotech company to skyrocket by as much as 404% in 2026. Let's find out why. Arcturus Therapeutics (ARCT) is a biotechnology company that develops messenger RNA (mRNA)-based medicines and vaccines. Instead of treating symptoms, Arcturus seeks to address the root cause of the problem by helping the body make the right proteins on its own. Valued at $194.3 million, ARCT stock dipped 64% last year, compared to the S&P 500 Index ($SPX) gain of 16%. However, the stock is up 10% so far this year. Nvidia CEO Jensen Huang Warns Investors That the AI Market Is Bigger Than They Realize With Over ‘One and a Half Million AI Models in the World' Novo Nordisk Is Getting a Major Boost from Amazon for Its New Weg
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at Citigroup Inc. from $9.00 to $7.00. They now have a "neutral" rating on the stock.MarketBeat
- Alloy Therapeutics Appoints Christian Cobaugh, Ph.D., as CEO of Alloy Genetic Medicines [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics to Attend Upcoming Investor ConferenceBusiness Wire
ARCT
Earnings
- 11/10/25 - Beat
ARCT
Sec Filings
- 1/8/26 - Form SCHEDULE
- 12/30/25 - Form S-3
- 12/19/25 - Form 4
- ARCT's page on the SEC website